NCT00831077已完成早期 1 期
Pharmacokinetic Properties of ORM-14540 and ORM-12741 After Administration of a Microdose of 14C-labelled Drug; An Open, Non-randomised, Single Dose, Single Centre Study in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Pharmacokinetic variables including: Area under the concentration-time curve (AUC), Maximum observed concentration (Cmax) at the end of infusion, Terminal elimination half-life (t½z), Total clearance (CL)
研究概览
简要总结
The purpose of this study is to determine pharmacokinetic parameters of ORM-12741 and ORM-14540 in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written informed consent (IC) obtained.
- •Good general health ascertained by detailed medical history and physical examinations.
- •Males between 18 and 45 years (inclusive).
- •Body Mass Index (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).
- •Weight 55-100 kg (inclusive).
排除标准
- •A predictable poor compliance or inability to communicate well with the investigator or study centre personnel.
- •Veins unsuitable for repeated venipuncture
- •Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric diseases as judged by the investigator.
- •Any condition requiring regular concomitant medication including herbal products or likely to need any concomitant treatment during the study.
- •Susceptibility to severe allergic reactions.
- •Intake of any medication that could affect the outcome of the study, within 2 weeks prior to the first study treatment or less than 5 times a half-life of the medication. Possible enzyme inducing drugs will be discussed case-by-case with the sponsor.
- •Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits, about 13 g of alcohol).
- •Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.
- •Inability to refrain from using nicotine-containing products during the stay at the study centre.
- •Inability to refrain from consuming caffeine-containing beverages during the stay in the study centre, e.g. propensity in getting headache when refraining from caffeine-containing beverages.
- •Blood donation or loss of significant amount of blood within 2 months prior to the screening visit.
- •Abnormal 12-lead electrocardiogram (ECG) finding of clinical relevance in supine position after resting for 10 minutes at the screening visit, for example:- QTc (calculated through the Bazett's formula) > 450msec,- PR < 120 msec or > 210 msec,- QRS < 70 msec or > 120 msec.
- •Heart rate (HR) < 45 beats/minute or > 100 beats/minute in supine position after resting for 10 minutes at the screening visit.
- •At the screening visit, systolic blood pressure (BP) < 90 mmHg or > 140 mmHg in supine position after resting for 10 minutes, diastolic BP < 50 mmHg or > 90 mmHg in supine position after resting for 10 minutes.
- •Any abnormal value of laboratory, vital signs, or physical examination, which may in the opinion of the investigator interfere with the interpretation of the test results or cause a health risk for the subject if he takes part into the study.
- •History of drug abuse or positive result in drug abuse test.
- •Positive serology to human immunodeficiency virus antigen/antibodies (HIVAgAb), hepatitis C virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).
- •Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the subject.
- •Participation in a clinical drug study within 3 months prior to the screening visit in this study, or earlier participation in a clinical study with ORM-
- •Exposure to 14C-labelled drugs or diagnostics within 12 months prior to the screening visit.
- •Men who are not practising clinically accepted method of contraception during the study and next 3 months after the study treatment administration.
研究组 & 干预措施
14C-ORM-14540
Active Comparator
干预措施: ORM-14540 (Drug)
14C-ORM-12741
Active Comparator
干预措施: ORM-12741 (Drug)
结局指标
主要结局
Pharmacokinetic variables including: Area under the concentration-time curve (AUC), Maximum observed concentration (Cmax) at the end of infusion, Terminal elimination half-life (t½z), Total clearance (CL)
时间窗: 72 hours
次要结局
- Safety variables including blood pressure (BP), heart rate (HR), electrocardiograms (ECGs), physical examination, laboratory safety variables (haematology, chemistry, serology and urinalysis) and adverse events (AEs).(Before and after study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Study of ORM-12741 in Healthy VolunteersHealthy VolunteersNCT00818740Orion Corporation, Orion Pharma12
已完成
1 期
Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)HealthyNCT02303860Orion Corporation, Orion Pharma15
已完成
1 期
Pharmacokinetic Study of Single Doses of ORM-12741HealthyNCT02319057Orion Corporation, Orion Pharma23
已完成
1 期
Safety and Tolerability Study With Single Ascending Doses of ORM-12741HealthyNCT00693316Orion Corporation, Orion Pharma120
已完成
1 期
Pharmacokinetic Study of LevosulpirideDyspepsiaNCT02481583Wuhan Union Hospital, China42